Global Orphan Diseases Market Growth (Status and Outlook) 2023-2029

Global Orphan Diseases Market Growth (Status and Outlook) 2023-2029

An orphan disease is defined as a condition that affects fewer than 200,000 people nationwide. This includes diseases as familiar as cystic fibrosis, Lou Gehrig's disease, and Tourette's syndrome, and as unfamiliar as Hamburger disease, Job syndrome, and acromegaly, or "gigantism." Some diseases have patient populations of fewer than a hundred.

LPI (LP Information)' newest research report, the “Orphan Diseases Industry Forecast” looks at past sales and reviews total world Orphan Diseases sales in 2022, providing a comprehensive analysis by region and market sector of projected Orphan Diseases sales for 2023 through 2029. With Orphan Diseases sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Orphan Diseases industry.

This Insight Report provides a comprehensive analysis of the global Orphan Diseases landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Orphan Diseases portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Orphan Diseases market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Orphan Diseases and breaks down the forecast by therapy area type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Orphan Diseases.

The global Orphan Diseases market size is projected to grow from US$ 254.7 million in 2022 to US$ 662.2 million in 2029; it is expected to grow at a CAGR of 14.6% from 2023 to 2029.

New rare diseases are discovered every year. Most are inherited and caused by alterations or defects in genes (mutations). Others can be acquired as a result of environmental and toxic conditions. Genes are pieces of DNA, part of the code that determines the traits and individual characteristics of all living things.

This report presents a comprehensive overview, market shares, and growth opportunities of Orphan Diseases market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by therapy area type
Ocology
Hematology
Neurology
Endocrinology
Cardiovascular
Respiratory
Immunotherapy
Others

Segmentation by application
Hospital Pharmacy
Retail Pharmacy
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Bristol-Myers Squibb
Novartis
Celgene
Roche
Pfizer
Alexion
Sanofi
Vertex Pharmaceuticals
GlaxoSmithKline
Merck
Abbvie

Please note: The report will take approximately 2 business days to prepare and deliver.